Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs
datacite.alternateIdentifier.citation | XENOBIOTICA,Vol.50,1490-1493,2020 | |
datacite.alternateIdentifier.doi | 10.1080/00498254.2020.1793031 | |
datacite.creator | Urzua, Natalia | |
datacite.creator | Messina, Maria Jimena | |
datacite.creator | Caverzan, Matias | |
datacite.creator | Prieto, Guillermo | |
datacite.creator | Lüders Post, Carlos | |
datacite.creator | Errecalde, Carlos | |
datacite.date | 2020 | |
datacite.subject.english | Levofloxacin | |
datacite.subject.english | dogs | |
datacite.subject.english | pharmacokinetics | |
datacite.subject.english | sucralfate | |
datacite.title | Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs | |
dc.date.accessioned | 2021-04-30T16:34:19Z | |
dc.date.available | 2021-04-30T16:34:19Z | |
dc.description.abstract | The study aims to establish the plasma pharmacokinetic parameters of levofloxacin in mixed-breed dogs, at a single dose of 5 mg/kg, intravenously, orally only and orally with sucralfate pre-treatment (1 g per animal), to evaluate its influence on antimicrobial absorption. Concentrations of levofloxacin in plasma were determined using high-performance liquid chromatography (HPLC) with fluorescence detection. After iv of levofloxacin, the mean (+/- SD) of AUC(0-24), Vz,t1/2 lambda z and MRT, was 19.05 +/- 6.4 mu g-h/ml, 2.43 +/- 0.5 L/kg, 7.93 +/- 1.41 hours and 8.7 +/- 1.5 hours, respectively. After oral administration, theC(max),t1/2 lambda z and bioavailability were 1.95 +/- 0.7 mu g/ml, 7.65 +/- 1.38 hours and 71.93 +/- 9.75%, respectively. In animals given an oral dose of levofloxacin with sucralfate pre-treatment, there was a significant decrease (p < 0.05) inC(max)(0.57 +/- 0.23 mu g/ml), AUC (5.73 +/- 2.26 mu g-h/ml) and bioavailability (31.92 +/- 14.19%). In the dogs studied, it is suggested that the dose 5 mg/kg of levofloxacin for both routes is inadequate to meet PK-PD targets for susceptible bacteria using breakpoints established by the Institute of Clinical and Laboratory Standards (CLSI). | |
dc.identifier.uri | http://repositoriodigital.uct.cl/handle/10925/3039 | |
dc.language.iso | en | |
dc.publisher | TAYLOR & FRANCIS LTD | |
dc.source | XENOBIOTICA | |
oaire.resourceType | Article | |
uct.catalogador | WOS | |
uct.indizacion | SCI |